{"id":"formoterol-powder-12-g-unit-dose","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Tremor"},{"rate":"5-10","effect":"Headache"},{"rate":"2-5","effect":"Palpitations"},{"rate":"2-5","effect":"Muscle cramps"},{"rate":"2-5","effect":"Nervousness"},{"rate":"1-3","effect":"Tachycardia"}]},"_chembl":{"chemblId":"CHEMBL1256786","moleculeType":"Small molecule","molecularWeight":"344.41"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Formoterol activates beta-2 adrenergic receptors on bronchial smooth muscle cells, triggering a cascade that increases intracellular cAMP levels, leading to smooth muscle relaxation and sustained bronchodilation. As a long-acting formulation, it provides extended therapeutic effect (12+ hours) compared to short-acting beta-agonists, making it suitable for maintenance therapy in chronic obstructive airway diseases.","oneSentence":"Formoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing bronchodilation and improved airflow.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:13:18.348Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD)"},{"name":"Asthma (maintenance therapy)"}]},"trialDetails":[{"nctId":"NCT07372573","phase":"NA","title":"Pressurized Meter Dose Inhaler V/S Dry Powder Inhaler","status":"NOT_YET_RECRUITING","sponsor":"University of Health Sciences Lahore","startDate":"2026-02-01","conditions":"Asthma (Diagnosis)","enrollment":210},{"nctId":"NCT00476268","phase":"PHASE3","title":"Efficacy and Tolerability of Beclometasone/Formoterol Single Inhaler in Patients With Moderate to Severe Persistent Asthma","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2004-02","conditions":"Asthma","enrollment":824},{"nctId":"NCT05553184","phase":"NA","title":"Activation of Brown Adipose Tissue Thermogenesis in Humans Using Formoterol Fumarate (GB10)","status":"COMPLETED","sponsor":"Université de Sherbrooke","startDate":"2022-07-05","conditions":"Type 2 Diabetes, Obesity","enrollment":12},{"nctId":"NCT01191424","phase":"PHASE2","title":"A Study Comparing the Pharmacokinetic, Pharmacodynamic and Safety of CHF 1535 (Fixed Combination of Beclomethasone + Formoterol) Administered Via the NEXT DPI, Versus the Free Combination of Licenced Beclomethasone DPI and Formoterol DPI in Asthmatic Adolescent and Adult Patients.","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2010-10","conditions":"Asthma","enrollment":57},{"nctId":"NCT00862394","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of CHF 1535 (BDP +FF) Inhalation Powder, Administered Via the NEXT Inhaler, Versus CHF 1535 (BDP +FF), Administered Via a pMDI, in Moderate to Severe Asthma","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2009-02","conditions":"Asthma","enrollment":783},{"nctId":"NCT01377428","phase":"PHASE4","title":"Efficacy of Indacaterol 150 µg Versus Formoterol","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2011-09","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":""},{"nctId":"NCT00443482","phase":"PHASE2","title":"Study to Demonstrate Equivalence of Formoterol 12 and 24 µg Delivered Via Two Types of Single Dose Dry Powder Inhalers (Concept1 and Aerolizer)","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-02","conditions":"Asthma","enrollment":50},{"nctId":"NCT01393145","phase":"PHASE3","title":"Efficacy and Safety Study of Formoterol/Fluticasone and Salmeterol/Fluticasone in Patients With Moderate-to-severe COPD","status":"WITHDRAWN","sponsor":"Ache Laboratorios Farmaceuticos S.A.","startDate":"2011-08","conditions":"Chronic Obstructive Pulmonary Disease, COPD","enrollment":""},{"nctId":"NCT00403637","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Single Doses of Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) Compared to Placebo in Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-11","conditions":"Asthma","enrollment":45},{"nctId":"NCT01043601","phase":"PHASE2","title":"Efficacy and Safety of Two Doses of Formoterol Fumarate MDI (PT005) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), Compared to Foradil® Aerolizer® as an Active Control","status":"WITHDRAWN","sponsor":"Pearl Therapeutics, Inc.","startDate":"2010-07","conditions":"COPD","enrollment":""},{"nctId":"NCT01349868","phase":"PHASE2","title":"PT005 MDI Dose Ranging Versus Foradil Aerolizer Study","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2011-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":50},{"nctId":"NCT00314574","phase":"PHASE3","title":"A Study of Omalizumab (Xolair) in Subjects With Moderate to Severe Persistent Asthma (EXTRA)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2005-12","conditions":"Asthma","enrollment":850},{"nctId":"NCT00396604","phase":"PHASE2, PHASE3","title":"Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-10","conditions":"Pulmonary Disease, Chronic Obstructive, COPD, Lung Diseases, Obstructive","enrollment":51},{"nctId":"NCT00393458","phase":"PHASE3","title":"Efficacy, Safety, and Tolerability of Once Daily Indacaterol in Chronic Obstructive Pulmonary Disease (COPD) Using Formoterol Twice Daily as Active Control","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1732},{"nctId":"NCT00463567","phase":"PHASE2, PHASE3","title":"26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-04","conditions":"Pulmonary Disease, Chronic Obstructive, COPD, Lung Diseases, Obstructive","enrollment":2059}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Foradil™"],"phase":"phase_3","status":"active","brandName":"Formoterol powder 12 µg/unit dose","genericName":"Formoterol powder 12 µg/unit dose","companyName":"Chiesi Farmaceutici S.p.A.","companyId":"chiesi-farmaceutici-s-p-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Formoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing bronchodilation and improved airflow. Used for Chronic obstructive pulmonary disease (COPD), Asthma (maintenance therapy).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}